The use of drug-eluting balloons for treatment of long-segment femoropopliteal artery obstructions has become widespread in recent years. The possibility to deliver a drug into the arterial wall with sustained antiproliferative effects, without leaving behind metal scaffolding, seems very promising. The current generation of drug-eluting balloons differs in the formulation of the drug (usually paclitaxel), technique of coating, and the elution excipients. Results of published randomized trials are reviewed in this report. A new innovative coating technique has been introduced recently. The PRIMUS® coronary drug-eluting balloon and the Legflow® peripheral drug-eluting balloon consist of paclitaxel nanoparticles that are embedded underneath the surface of the balloon as well as inside a new shellolic acid drug-release matrix. Risk for dislodgement of the paclitaxel particles is minimized in the newest generation of drug-eluting balloons. Short-term in vitro and in vivo results of this stable, coated balloon are promising, and large randomized trials have been started recently to gather more longterm and robust clinical data.

Angioplasty, Atherosclerosis, Paclitaxel, Peripheral artery disease
hdl.handle.net/1765/85572
The Journal of Cardiovascular Surgery: a journal on cardiac, vascular and thoracic surgery
no subscription

de Vries, J.-P.P.M, Karimi, A, Fioole, B, van Leersum, M, Werson, D.A.B, & Van Den Heuvel, D.A.F. (2013). First- and second-generation drug-eluting balloons for femoro-popliteal arterial obstructions: Update of technique and results. The Journal of Cardiovascular Surgery: a journal on cardiac, vascular and thoracic surgery (Vol. 54, pp. 327–332). Retrieved from http://hdl.handle.net/1765/85572